Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients (Q91910595)
Jump to navigation
Jump to search
scientific article published on 11 December 2019
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients |
scientific article published on 11 December 2019 |
Statements
Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients (English)
Toshimitsu Hamasaki
Kaori Onda
Takashi Nojiri
Masato Aragaki
Nao Horie
Norihiro Sato